
Poxel Secures New Patent in Japan for Imeglimin’s Use in Type 2 Diabetes Patients with Renal Impairment
Poxel Secures New Patent in Japan for Imeglimin’s Use in Type 2 Diabetes Patients with Renal Impairment POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company specializing in innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic…










